Status:
UNKNOWN
Thrombin Generation in Liver Transplant Surgery
Lead Sponsor:
University Health Network, Toronto
Conditions:
Liver Transplantation
Thrombin
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective observational study of 100 patients undergoing liver transplantation at a single centre. Thrombin generation and kinetics will be assessed using a novel point-of-care device, and...
Detailed Description
Liver transplantation is the only curative option for end stage liver disease, but is associated with high morbidity and mortality. End stage liver disease is known to be accompanied by dysregulated c...
Eligibility Criteria
Inclusion
- All adult patients (\> 18 years of age) proceeding to imminent (within 24 hours) liver transplantation surgery at Toronto General Hospital will be offered participation.
- Patients should have end stage liver disease necessitating transplantation. All etiologies of end stage liver disease will be accepted.
Exclusion
- \- Patients who are unable to consent to the study or who refuse participation will be excluded.
Key Trial Info
Start Date :
March 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04762550
Start Date
March 8 2021
End Date
January 1 2022
Last Update
May 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto General Hospital - University Health Network
Toronto, Ontario, Canada, M5G 2C4